94193-52-9

Upstream product

• 94193-38-1 N-Cyclohexyl-N-methyl-4-(3-formyl-4-nitrophenyl)-oxybutyramide 
• 100-60-7 N-methylcyclohexylamine 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 94193-35-8 ethyl 4-((3-formyl-4-nitrophenyl)oxy)butyrate 
• 94193-36-9 4-(3-formyl-4-nitrophenyl)oxybutanoic acid 
• 94193-37-0 4-(3-Formyl-4-nitro-phenoxy)-butyryl chloride 

Downstream Products

• 105763-78-8 N-cyclohexyl-N-methyl-4-(4-amino-3-carboxyphenoxy)butyramide hydrochloride 

Relevant academic research and scientific papers

1H-1,2,4-thiadiazolo(3,4-b)quinazolin-5-one-2,2-dioxides, and a method for increasing the cardiac output of a mammal with them

1H-1,2,4-thiadiazolo[3,4-b]quinazolin-5-one-2,2-dioxides are disclosed. These compounds are useful as caridotonic agents. A preferred compound is 7-(n-cyclohexyl-N-methyl-4-amino-4-oxobutyloxy)-1H-1,2,4-thiadiazolo[3,4-b]quinazolin-5-one-2,2-dioxide.

Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide

Evaluation of a series of lactam heterocyclic analogues of cilostamide as inhibitors of cyclic AMP phosphodiesterase derived from both human platelets and rat heart in comparison with their corresponding methoxy-substituted heterocycles has revealed that the N-cyclohexyl-N-methyl-4-oxybutyramide side chain of 2 is an important lipophilic and/or steric pharmacophore. Attachment of this side chain to the parent heterocycle of the potent cyclic AMP phosphodiesterase inhibitor anagrelide afforded the hybrid structure RS-82856, shown to be more potent than either of its progenitors as an inhibitor of cyclic AMP phosphodiesterase or of ADP-induced platelet aggregation. The available in vitro data suggest that 1 possesses potentially useful antithrombotic and cardiotonic properties.